SynAct Pharma AB is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation.
Our lead asset resomelagon (AP1189) is being evaluated in three Phase 2 clinical programs: rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN, a form of nephrotic syndrome), and virus-induced respiratory insufficiency (VIRI) like that seen in COVID-19.
In January of 2023, SynAct completed the acquisition of TXP Pharma AG, significantly expanding its melanocortin technology portfolio with complimentary peptide agonists that can be tailored to a wide range of autoimmune and inflammatory conditions.